AMRI strategically expands to produce rare disease products

By The Science Advisory Board staff writers

April 30, 2021 -- Albany Molecular Research (AMRI) has expanded access to its accelerated solutions platform from research and development to manufacturing for orphan and rare disease products.

The contract research, development, and manufacturing organization (CRDMO) has made investments globally to expand its scale and compound handling capabilities. The expansion includes additional suites at its Albany, NY, facility that meet good manufacturing practice (GMP) requirements and are designed to manufacture batch sizes of 10-15 kg.

At its Grafton, WI, location, the company has added liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry instruments in expanded laboratory space. AMRI is also adding expert teams at its facilities in Albany, Grafton, and Glasgow, Scotland.

Rare diseases are conditions that affect a limited population, defined in the U.S. as fewer than 200,000 people and in the European Union as fewer than one in 2,000 people.

AMRI ups hydroxychloroquine sulfate API production
AMRI Global will boost production of hydroxychloroquine sulfate active pharmaceutical ingredients (API) due to its potential effectiveness in treating...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter